ING Groep NV Decreases Position in Intuitive Surgical, Inc. (NASDAQ:ISRG)

ING Groep NV cut its position in Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 42.9% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 72,248 shares of the medical equipment provider's stock after selling 54,248 shares during the period. ING Groep NV's holdings in Intuitive Surgical were worth $35,493,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. Mirador Capital Partners LP lifted its position in shares of Intuitive Surgical by 1.4% during the third quarter. Mirador Capital Partners LP now owns 3,526 shares of the medical equipment provider's stock worth $1,732,000 after purchasing an additional 50 shares in the last quarter. Advisors Asset Management Inc. lifted its position in shares of Intuitive Surgical by 18.1% during the first quarter. Advisors Asset Management Inc. now owns 7,380 shares of the medical equipment provider's stock worth $2,945,000 after purchasing an additional 1,129 shares in the last quarter. Consolidated Planning Corp lifted its position in shares of Intuitive Surgical by 17.4% during the third quarter. Consolidated Planning Corp now owns 8,099 shares of the medical equipment provider's stock worth $3,979,000 after purchasing an additional 1,198 shares in the last quarter. Healthcare of Ontario Pension Plan Trust Fund lifted its position in shares of Intuitive Surgical by 617.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 89,069 shares of the medical equipment provider's stock worth $39,622,000 after purchasing an additional 76,649 shares in the last quarter. Finally, Brookstone Capital Management lifted its position in shares of Intuitive Surgical by 22.4% during the second quarter. Brookstone Capital Management now owns 12,530 shares of the medical equipment provider's stock worth $5,340,000 after purchasing an additional 2,289 shares in the last quarter. 83.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Intuitive Surgical

In other Intuitive Surgical news, EVP Robert Desantis sold 396 shares of the stock in a transaction that occurred on Monday, August 26th. The stock was sold at an average price of $486.88, for a total transaction of $192,804.48. Following the completion of the sale, the executive vice president now directly owns 5,506 shares of the company's stock, valued at approximately $2,680,761.28. This trade represents a 6.71 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Director Amy L. Ladd sold 450 shares of the stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $490.28, for a total value of $220,626.00. Following the sale, the director now directly owns 821 shares of the company's stock, valued at $402,519.88. The trade was a 35.41 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 91,178 shares of company stock valued at $45,897,071 over the last ninety days. Insiders own 0.90% of the company's stock.

Analyst Ratings Changes

ISRG has been the subject of a number of recent research reports. Wells Fargo & Company boosted their price target on shares of Intuitive Surgical from $466.00 to $549.00 and gave the stock an "overweight" rating in a research note on Friday, October 18th. Piper Sandler reissued an "overweight" rating and set a $538.00 price target (up from $495.00) on shares of Intuitive Surgical in a research note on Friday, October 18th. Barclays boosted their price target on shares of Intuitive Surgical from $430.00 to $490.00 and gave the stock an "overweight" rating in a research note on Thursday, July 18th. JPMorgan Chase & Co. upped their target price on shares of Intuitive Surgical from $495.00 to $575.00 and gave the company an "overweight" rating in a research note on Friday, October 11th. Finally, Evercore ISI reaffirmed a "cautious" rating on shares of Intuitive Surgical in a research note on Friday, October 18th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fourteen have given a buy rating to the stock. Based on data from MarketBeat.com, Intuitive Surgical presently has an average rating of "Moderate Buy" and an average price target of $513.74.

Intuitive Surgical Stock Performance

ISRG stock traded up $1.11 during trading on Thursday, reaching $537.80. 1,908,278 shares of the company traded hands, compared to its average volume of 1,461,343. Intuitive Surgical, Inc. has a 12 month low of $291.39 and a 12 month high of $544.38. The business has a 50 day simple moving average of $496.95 and a 200 day simple moving average of $455.65. The company has a market capitalization of $191.55 billion, a price-to-earnings ratio of 86.28, a price-to-earnings-growth ratio of 5.28 and a beta of 1.39.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last announced its quarterly earnings data on Thursday, October 17th. The medical equipment provider reported $1.56 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.24 by $0.32. Intuitive Surgical had a return on equity of 13.41% and a net margin of 28.51%. The firm had revenue of $2.04 billion during the quarter, compared to analysts' expectations of $2.01 billion. As a group, research analysts forecast that Intuitive Surgical, Inc. will post 5.45 EPS for the current year.

Intuitive Surgical Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.